SCHEMBL4116149

SCHEMBL4116149

COc1ccc(N(Cc2ccnc(-c3ccccc3)c2)C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.53
GPR119 Q8TDV5 5/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HDAC1 Q13547 1/20 0.44
USP30 Q70CQ3 1/20 0.44
YAP1 P46937 2/20 0.44
TGFBR1 P36897 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122387 0.94 SLC2A1 (0.54) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4117193 0.92 SLC2A1 (0.50) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4109784 0.92 SLC2A1 (0.49) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4123371 0.92 SLC2A1 (0.49) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4123730 0.92 GPR119 (0.54) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4123050 0.90 SLC2A1 (0.49) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4109826 0.89 SLC2A1 (0.49) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4108456 0.89 SLC2A1 (0.49) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4116457 0.89 SLC2A1 (0.51) SLC2A1GPR119HTTMEN1KMT2A
SCHEMBL4126236 0.89 SLC2A1 (0.50) SLC2A1GPR119HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143430-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR KOWA CO., LTD. (JP) 2009-06-04 US disclosed
US-20090143430-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR KOWA CO., LTD. (JP) 2009-06-04 US disclosed
US-20060040986-A1 Erythropoietin production accelerator KOWA CO., LTD. (JP) 2006-02-23 US disclosed
EP-1568691-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR Kowa Co., Ltd. (JP) 2005-08-31 EP disclosed
US-20050176764-A1 Medicine for treating cancer KOWA CO., LTD (JP) 2005-08-11 US disclosed
US-6867221-B2 Cyclic amine compounds and pharmaceutical composition containing the same KOWA CO., LTD. (JP) 2005-03-15 US disclosed
EP-1422219-A1 CYCLIC AMINE COMPOUND Kowa Co., Ltd. (JP) 2004-05-26 EP disclosed
US-20040010147-A1 Cyclic amine compounds and pharmaceutical composition containing the same KOWA CO., LTD. (JP) 2004-01-15 US disclosed
US-6605620-B1 Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration KOWA CO., LTD. (JP) 2003-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176764-A1 Medicine for treating cancer HDAC4, HDAC3, NR4A3 SLC2A1 1517/4885GPR119 524/4885HTT 1421/4885
US-20060040986-A1 Erythropoietin production accelerator EPOR, GHRHR, ARL1 SLC2A1 3455/4885GPR119 66/4885HTT 1190/4885
US-20090143430-A1 ERYTHROPOIETIN PRODUCTION ACCELERATOR EPOR, GHRHR, ARL1 SLC2A1 3455/4885GPR119 66/4885HTT 1190/4885
US-20040010147-A1 Cyclic amine compounds and pharmaceutical composition containing the same HRH3, HRH4, CNKSR1 SLC2A1 2240/4885GPR119 676/4885HTT 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.